Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Frequently asked questions
What sector does Parabilis Medicines, Inc. Common Stock (PBLS) operate in?
Parabilis Medicines, Inc. Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Parabilis Medicines, Inc. Common Stock (PBLS) current stock price?
As of the latest data, Parabilis Medicines, Inc. Common Stock stock price is $25.64, with a previous close of $25.03. Parabilis Medicines, Inc. Common Stock gained $0.61 in the last trading session, representing a 2.44% increase.
What is Parabilis Medicines, Inc. Common Stock (PBLS) current market capitalization?
Parabilis Medicines, Inc. Common Stock market cap is approximately 3.13 billion.
What is Parabilis Medicines, Inc. Common Stock (PBLS) Earnings Per Share (EPS)?
The trailing EPS is -$9.30, and the forward EPS is -$2.19.
What is Parabilis Medicines, Inc. Common Stock (PBLS) EBITDA?
Parabilis Medicines, Inc. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -51.66 million.
Does Parabilis Medicines, Inc. Common Stock (PBLS) pay dividends?
No. Parabilis Medicines, Inc. Common Stock does not pay a dividend.
How did Parabilis Medicines, Inc. Common Stock (PBLS) perform in its most recent earnings report?
In the last report (June 30, 2026), Parabilis Medicines, Inc. Common Stock posted an EPS surprise of -1,231.25% and a revenue surprise of -99.11%.
When is Parabilis Medicines, Inc. Common Stock (PBLS) next earnings report?
Parabilis Medicines, Inc. Common Stock is expected to release its next earnings report on September 30, 2026.
What is Parabilis Medicines, Inc. Common Stock (PBLS) beta (volatility) score?
Parabilis Medicines, Inc. Common Stock has a beta of 0.003, indicating lower volatility than the overall market.
